Clinical News

Clinical Status

<div class="articleContainer"><div class="articleWrapper"><div class="articleContent"><h1 class="text title">VEL-0230: Phase Ia start</h1><div class="byline">WIR Staff</div><div class="date"></div></div></div></div>

VTJGc2RHVmtYMStGQ2tBZGtUSTNhS2J0NWdIQ01zbEtSUFdrcmlBdlpSeHlzdTl5eFhqWXRobXprZjZwTGZpbmcxbWcyUmFMcWdqZW9NbVE0SjQrMFpEMXE2SldwNXJXbnFMSTBkR2Z1SklWNldnbjQ1Z1NrZDkvcGFoUDZnK3dvRnVmbGtTTndYcFJpcWxzL2FDaWRlV01tSmU4ZHpacmYrYnpGL3ZRYWJDSHJvaHFiTDBUUEFTdnNtZW5mVjNCYXI2K000TGMxd3JYQUladVY4R1FQSk5FRm5qV2tSUzVJQ1UzNkxqUENUdjVZbjRDOXZFRmxwdnhxRjlUczdpaGNzblI3RkZ1UC8wNXhMcXFBcFFGSjhZc2VoNTgyY2hwekNhR25PNkdTdEErdjNLT2FkTDZXK0YvN0NLMXhSeTMwMjhHYTBXSjFaWTZneERhckszZDhXcERBM0ZVcjYrT080WDNCVWVHZUJGRVF4Q09xN0p1cUgyRDc1NFkwOGhOdE15ellwNmNJbmZBOTZjMHl2azk3UVZ6dnJjUDRuSmlKWXdoSGdNRWFTWFp4YStjWHhGN2hLQXFVQm5TYUFwQ1F5UXJaaWVmMDFmamRWVlpqUDBJdUhZc1J1TmRWbkg3aXR5THgxajYxTmErYWsxREcyOUs1dHBxN0hMelAwMnZKaW9jTDcrMWdTYlI2KzFxcnpLbVpXdjFDU0w3aG04TlMzNkZUMi9RN1pwZURETW9aY09DeFhtczR6VmxMOU1tUERsbC9ZeWxyeXQ2QndLUXdCeUlhNlBKRStobU1ZY0ZHVWRsbXBSbVdMOUZyVk4wSElpMU56ZEFUUDZnd2tNaEs0eG9FTjNLeHR5Y01kTXdtTlBObE43YU1DbFRsMGVyV1VvbFJGR2ZmOGNlWE1Zdmp3Z2RjODY5U3NidUFWZEc3dkR6VWQvZFg0Vm9HS2hGQm9ianVUVHJEUnFxTlJ3ZGp1K1VhSXBpOHBJYlRsQ1h4bzA5SlVqVXhSbjBKc3dUM2JNOExmWmtBLy9MeEZ4WFkwYmxFSElmUWtMcmI4clFSR3R3SDF0VFlnUU1KRHIzS1kyYzZwcFRnNU45MFAxYmZkVUduZjhMcFVhVURqZ2tIbHF2UTRXeFJvOUphZzR5NXBhVDdOd3cweUdEeUFNMnp0UTJuaFY0WDB5bnBrWTlBeUkxZWEwbDBDL0FvcDBGQWdWLzUxTDB2Zzc1Tkc0SlJiRlNVOEFodTZnZTZ1S1lXQkpqdVRWWE81NWFSQnhJdXZJOU5sVitKOTJ4aHl5QVhNM3Q2SXNyUk0rbVdBT1J0b3JyenZXVGdTODdudHI0R1BNODlCa1k1OHV6d0JvU0htOGZISjlWbU9EMWJ1V3ZLZXpqTGwrVXFnNjMraXJBc3JJZkNMdmJmai9CVXQ4TDRWTUNGZjRscEJoMEd0c1RURmVPNGUwQU1UR3NxTUNiYkNjSUZtb3VjaTYxZEdtMW9NTUZPTitvbEF0R1hyT3g4KzJxN1VoN29wS2E0NkpwT3dVY01tTXZDMXRFOXVOUWFmMDloYlRBSDBNanZ3ZytqdGhiRjRzNk96MFdwQ3dKeHRTRi9lVDQxK0YvbHVCS0k1cVF5WFBvNDZtMWttUEdWa1Z3UUdJS2FsOEpyQWVMOENGN2VOblFiKzg9

In 1Q08, Velcura plans to begin an open-label, dose-escalation Phase Ia trial of oral VEL-0230. ......

cancer

VEL-0230: Phase Ia start

BioCentury AI Connector

BC AI

My Workspace

Featured Analysis

Articles by Category

Discovery & Translation Analysis

Horizon Scanning

Hot Topics

Scene Setters & Special Reports

White Papers

Analysis

BCIQ Data

Innovation Distillery

Company Profiles

Deal Profiles

Product Profiles

Target Profiles

Financial Dashboards

IPO Dashboard

BCIQ Brochure

BCIQ Data Coverage Policy

BCIQ

BioCentury This Week

The BioCentury Show

Webinars

Podcasts 

All Events

BioCentury Grand Rounds Europe 2026

Grand Rounds — Europe

The BioCentury-BayHelix China Healthcare Summit

China Healthcare Summit

BioCentury-BayHelix East-West Summit 2027

East-West Biopharma Summit

Bio€quity Europe

BioCentury Grand Rounds U.S. 2027

Grand Rounds — U.S.

Sponsorship & Branding Inquiry

Media Kit

Events

Contact Us

Customer Resource Center

Upgrade Subscription

Change Password

Career Opportunities

Contact

Home